Cataract surgery becomes refractive: learn how IOL choices and preop counseling across distance, intermediate and near turn 20/20 into 20/happy.
|Videos|October 1, 2022
Reviewing the AAO cornea preferred practice patterns: Corneal edema, opacifications, ectasia and bacterial keratitis
Author(s)David Hutton, Emily Kaiser Maharjan
David Hutton discusses the AAO 2022 presentation, "Corneal Edema, Opacifications, Ectasia, and Bacterial Keratitis: Diagnosis and Treatment Strategies from the Preferred Practice Pattern Guidelines," with speaker Francis S. Mah, MD.
Advertisement
Advertisement
Related to this article
Dry eye cases rise with heavy screen use and younger patients; learn modern workups spotlighting MGD, etiology-driven treatments, and collaborative care reshaping outcomes.
Optometrist–ophthalmologist co-management targets dry eye early, improves cataract and refractive surgery satisfaction, and uses advanced diagnostics and treatments for healthier ocular surfaces.
June brings FDA clearance for Lumvoa, key retina and glaucoma trials, device deals, and hard truths on AI performance in eye care.
The RMAT designation opens the door to a faster development pathway for EO2002 as a minimally invasive alternative to corneal transplantation, while Emmecell also advances a cell therapy for geographic atrophy.
Andrew G. Lee, MD, and Drew Carey, MD, discuss findings from a retrospective study examining ischemic stroke risk in patients with non-arteritic anterior ischemic optic neuropathy and the implications for vascular risk factor management.
Patients with polyendocrine metabolic ovarian syndrome have higher ocular disease prevalence.
Length and width, not thickness, emerge as key drivers of higher-order aberrations.
Advertisement
Advertisement
Trending on Eye Care Network - Ophthalmology Times
1
FDA approves phentolamine ophthalmic solution 0.75% (Ryzumvi) for presbyopia
2
Duravyu misses noninferiority end point in phase 3 LUCIA wet AMD trial
3
Alvotech files first known aflibercept 8 mg biosimilar with EMA
4
Beyond slowing atrophy: Optogenetic therapy targets vision lost to GA
5